三生製藥(01530.HK)擬向輝瑞配發3114萬股 籌資約7.85億港元
格隆匯7月24日丨三生製藥(01530.HK)公告,就與輝瑞就PD-1/VEGF雙特異性抗體(SSGJ-707)訂立許可協議事項,許可協議所訂明的所有先決條件已達成,因此,許可協議自2025年7月24日起生效。
構成許可協議項下先決條件之一的選擇權協議亦已生效。選擇權協議向輝瑞授予獨家許可,以在中國開發和商業化許可產品。集團將收到總額不超過150百萬美元的不可退還且不可抵扣的期權金及行權金。選擇權協議項下擬行使的相關選擇權獲行使後,許可協議項下的許可地區將爲全球。
於2025年7月24日,公司與輝瑞訂立認購協議,據此,輝瑞已有條件同意認購而公司已有條件同意發行及配發3114萬股認購股份,認購價爲每股25.2055港元,總金額約爲785.0百萬港元。認購股份相當於:(i)公司於本公告日期現有已發行股本約1.30%;及(ii)公司經發行及配發認購股份而擴大已發行股本約1.28%。
認購事項所得款項淨額將約爲785.0百萬港元。公司擬將(i)約628.0百萬港元(佔所得款項淨額的80%)用於豐富產品管線中的臨牀及臨牀前項目的全球研發佈局,以及改善生產設施;及(ii)約157.0百萬港元(佔所得款項淨額的20%)用於其它一般公司用途。
董事認爲,認購事項爲達致以下各項的良機:(i)爲公司籌得額外資金,及以輝瑞作爲戰略投資者,提升公司的股東基礎;及(ii)進一步增強公司的業務增長併爲公司管線開發計劃提供更多支持與靈活性,釋放其資產在全球市場的更大潛力,進而爲公司及其股東創造可持續長期回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.